Akums Drugs & Pharmaceuticals, a contract development and manufacturing organization (CDMO), has announced the launch of a pioneering Ripasudil-Timolol combination therapy for glaucoma treatment.
This DCGI-approved product represents a significant advancement in ophthalmic care, with Akums becoming the first Indian CDMO to receive approval for this innovative formulation.
Glaucoma ranks as the second leading cause of irreversible but preventable blindness worldwide, with India contributing to 23.5% of the global burden. The condition remains third among causes of vision impairment in India, after cataract and refractive errors. Also, Ocular hypertension is closely linked to glaucoma, many eye care professionals consider ocular hypertension to be a precursor or warning sign for glaucoma.
The new combination therapy offers a dual mechanism of action for superior intraocular pressure (IOP) control: Ripasudil enhances aqueous humor outflow through the trabecular meshwork, while Timolol reduces aqueous humor production. This synergistic approach delivers more substantial and sustained IOP reduction compared to single-drug treatments.
The single combination drop formulation significantly simplifies treatment regimens, addressing a major challenge in glaucoma management—patient adherence. By combining two medications into one product, patients benefit from enhanced convenience and potentially improved compliance.
"With the rising prevalence of glaucoma in India, introducing therapies that enhance efficacy and patient compliance is crucial," said Sandeep Jain, Managing Director of Akums Drugs & Pharmaceuticals.
Akums will utilise its state-of-the-art manufacturing facilities to ensure consistent supply and broad availability of this breakthrough therapy.
